pediatric exclusivity

Related by string. Pediatric Exclusivity * pediatrics . PEDIATRIC . PEDIATRICS . Pediatrics . Pediatric : Elizabeth Glaser Pediatric . Pediatric Intensive Care . Pediatrics recommends . pediatric oncology . pediatric dentist . pediatric dentists / Exclusivity : utilizing exclusivity . exclusivity periods . Hatch Waxman exclusivity . exclusivity clause . Exclusivity Agreement * *

Related by context. Frequent words. (Click for all words.) 64 Act PDUFA date 62 Hatch Waxman 62 methylnaltrexone 61 Orphan Drug status 61 Marketing Authorization 61 Hatch Waxman Act 60 Jevtana 60 Arixtra 59 Paragraph IV certification 59 Plavix patent 59 Promacta 59 Hycamtin 59 Orphan Drug designation 59 TORISEL 58 Mylotarg 58 FIRAZYR 58 Torisel 58 ADDERALL XR 58 Treximet 58 Fast Track Designation 58 JANUVIA 57 Protopic 57 exclusivity periods 57 Mutual Recognition Procedure 57 See BioWorld Today 57 PLAVIX 57 Stalevo 57 exclusivity 57 orphan designation 56 Act PDUFA 56 ISENTRESS 56 Icatibant 56 Camptosar 56 PDUFA date 56 Opana ER 56 Investigational Device Exemption 56 VIBATIV 56 Orphan Drug Status 56 Complete Response 56 LIALDA 56 TYKERB 56 Orphan Medicinal Product 56 Exalgo 56 Valcyte 56 European Medicines Evaluation 56 Relistor 56 Cimzia R 56 Caduet 55 supplemental Biologics License Application 55 CHMP opinion 55 romiplostim 55 Gemzar 55 eltrombopag 55 sBLA 55 Glumetza 55 Yervoy 55 Famvir 55 Biologics License Application 55 Priority Review 55 alogliptin 55 silodosin 55 Topiramate 55 Avastin bevacizumab 55 Stelara 55 Oxandrin 55 Loramyc ® 55 ANDAs 55 Orphan Drug Act 55 Vilazodone 55 VIMOVO 55 ONSOLIS 55 muraglitazar 54 SANCTURA XR 54 NOXAFIL 54 Aciphex 54 PDUFA 54 alvimopan 54 Fast Track designation 54 Cozaar 54 antiemetic 54 Pivotal Phase III 54 Seroquel XR 54 Marketing Authorization Application 54 REMICADE ® 54 SILENOR TM 54 Factive 54 ZOSTAVAX 54 ROTATEQ 54 NUVIGIL 54 pantoprazole 54 tocilizumab 54 Bupropion 54 Ondansetron 54 bazedoxifene 54 entecavir 54 Extended Release Tablets 54 Aldara 54 GRAS status 53 PROMACTA 53 Prescription Drug User Fee 53 Orphan Drug Designation

Back to home page